60 Degrees Pharmaceuticals (SXTP) Metrics: History & Chart

60 Degrees Pharmaceuticals, Inc.(SXTP)

Biotechnology · Washington, DC

$1.11-0.33 (-22.92%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.

Washington, DC

3 employees

www.60degreespharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Geoffrey Stuart Dow

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	+15.20%
30D Total Return	+56.64%
YTD Total Return	-29.06%
1Y Total Return	-74.65%
3Y Total Return	-99.10%
5Y Total Return	N/A
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-29.06%
2025	-92.13%
2024	-89.46%
2023	N/A
2022	N/A
2021	N/A

CAGR TTM	-74.48%
CAGR 3Y	-79.23%
CAGR 5Y	N/A
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	4.08
PE Ratio Avg TTM	8.63
PE Ratio Avg 3Y	8.63
Current VS TTM Avg	-52.70%
Current VS 3Y Avg	-52.70%
Current VS 5Y Avg	-52.70%

All Metrics

SXTP Valuation Metrics

SXTP Stock Price Metrics

SXTP Dividend Metrics

SXTP Growth Rate Metrics

SXTP Discounted Cash Flow Metrics

SXTP Returns By Period

SXTP Yearly Returns

SXTP Average Annual Returns By Period (CAGR)

SXTP Revenue Metrics

SXTP PE Ratio Metrics

SXTP PS Ratio Metrics

SXTP PB Ratio Metrics

SXTP Price to Free Cash Flow Ratio Metrics

SXTP Debt to Equity Ratio Metrics

SXTP PEG Ratio Metrics

SXTP FCF Yield

SXTP Earnings Yield

SXTP EBITDA Yield

SXTP OCF Yield

SXTP EV/EBIT Ratio Metrics

SXTP EV/EBITDA Ratio Metrics

SXTP EV/Assets Ratio Metrics

SXTP EV/Sales Ratio Metrics

SXTP Current Ratio Metrics

SXTP Quick Ratio Metrics

SXTP ROIC Metrics

SXTP Return on Assets Metrics

SXTP Return on Equity Metrics

SXTP Net Profit Margin Metrics

SXTP Gross Profit Margin Metrics

SXTP Tax Rate Metrics

PS Ratio	3.44
PS Ratio Avg TTM	2.65
PS Ratio Avg 3Y	4.17
Current VS TTM Avg	+30.00%
Current VS 3Y Avg	-17.45%
Current VS 5Y Avg	-25.02%

PB Ratio	N/A
PB Ratio Avg TTM	N/A
PB Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.06
Debt/Equity Ratio Avg TTM	0.05
Debt/Equity Ratio Avg 3Y	0.04
Current VS TTM Avg	+24.83%
Current VS 3Y Avg	+47.03%
Current VS 5Y Avg	+128.09%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	24.51%
Earnings Yield Avg TTM	11.42%
Earnings Yield Avg 3Y	11.42%
Current VS TTM Avg	+114.68%
Current VS 3Y Avg	+114.68%
Current VS 5Y Avg	+114.68%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.69
Ev/Assets Ratio Avg TTM	0.22
Ev/Assets Ratio Avg 3Y	0.16
Current VS TTM Avg	+209.32%
Current VS 3Y Avg	+333.53%
Current VS 5Y Avg	-46.17%

Ev/Sales Ratio	2.66
Ev/Sales Ratio Avg TTM	0.98
Ev/Sales Ratio Avg 3Y	4.92
Current VS TTM Avg	+171.21%
Current VS 3Y Avg	-45.98%
Current VS 5Y Avg	-95.59%

Current Ratio	2.32
Current Ratio Avg TTM	2.69
Current Ratio Avg 3Y	2.91
Current VS TTM Avg	-13.67%
Current VS 3Y Avg	-20.04%
Current VS 5Y Avg	-0.84%

Quick Ratio	1.78
Quick Ratio Avg TTM	2.27
Quick Ratio Avg 3Y	2.55
Current VS TTM Avg	-21.77%
Current VS 3Y Avg	-30.35%
Current VS 5Y Avg	+0.02%

ROIC	(321.28%)
ROIC Avg 3Y	(187.39%)
ROIC Avg 5Y	(177.89%)
Current VS 3Y Avg	-71.45%
Current VS 5Y Avg	-80.60%
Current VS 10Y Avg	-80.60%

ROA	(189.43%)
ROA Avg TTM	(37.35%)
ROA Avg 3Y	(35.33%)
Current VS TTM Avg	-407.23%
Current VS 3Y Avg	-436.18%
Current VS 5Y Avg	-593.47%

ROE	(310.33%)
ROE Avg TTM	(236.43%)
ROE Avg 3Y	(162.24%)
Current VS TTM Avg	-31.26%
Current VS 3Y Avg	-91.28%
Current VS 5Y Avg	-91.28%

Net Profit Margin	(730.23%)
Net Profit Margin Avg TTM	(1020.18%)
Net Profit Margin Avg 3Y	(1155.99%)
Current VS TTM Avg	+28.42%
Current VS 3Y Avg	+36.83%
Current VS 5Y Avg	+54.96%

Gross Profit Margin	19.42%
Gross Pft Margin Avg TTM	32.44%
Gross Pft Margin Avg 3Y	28.82%
Current VS TTM Avg	-40.14%
Current VS 3Y Avg	-32.61%
Current VS 5Y Avg	+194.27%

Tax Rate	0.01%
Tax Rate Avg 3Y	0.01%
Tax Rate Avg 5Y	0.01%
Current VS 3Y Avg	+81.40%
Current VS 5Y Avg	+81.40%
Current VS 10Y Avg	+81.40%